Jul 2021   Rivamist® nasal spray human factors and engineering studies successfully completed.

Feb 2021   Second United States patent granted for our nasal drug delivery technology.

Oct 2020   Australian patent granted for our nasal drug delivery technology.

Aug 2020   European patent granted for our nasal drug delivery technology.   

Jul 2020   Pharmacokinetic bridge study of Rivamist® nasal spray and Exelon® oral capsule successfully completed.

• Nasal delivers twice the rivastigmine exposure as oral at an equivalent 3 mg dose
• Rivastigmine plasma concentration shown for nasal 4 mg and oral 3 mg (below)

AusIndustry funding support acknowledged, ​​ACTRN12619001513101, Mean ± SD, n= 16, ​Scientific title: A randomised, crossover, two period, pharmacokinetic, bioavailability and safety study of a single dose of the novel rivastigmine nasal spray and single dose rivastigmine (Exelon, registered trademark) oral capsule in young healthy adult males. Exelon is a registered trademark of Novartis Corp.

Sep 2019   AusIndustry AC grant to support the development of our proprietary rivastigmine nasal spray for Alzheimer's and Parkinson's disease dementia.

Aug 2019   United States patent granted for our nasal drug delivery technology.

---

Journal Publication

• Morgan TM, Soh B. Absolute Bioavailability and Safety of a Novel Rivastigmine Nasal Spray in Healthy Elderly Individuals. Br J Clin Pharmacol. 2017 83(3):510-516   PMID: 27639640   DOI: 10.1111/bcp.13133​

---

Conference Posters

• Morgan TM. Deconvolution of Nasal Absorption of Rivastigmine in Humans and Future Clinical Development. J Prev Alz Dis 2016. 3(4):353; P2-39.
• Morgan TM. Absolute bioavailability and safety of a novel rivastigmine intranasal spray in healthy elderly individuals. J Prev Alz Dis 2015. 2(4):269-396; P2-55.